SWOG clinical trial number
SWOG-9305 (CALGB-8984)

Evaluation of Topotecan in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Phase II

Closed
Phase
Accrual
75%
Published
Abbreviated Title
Evaluation of Topotecan in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Phase II
Activated
01/15/1994
Closed
05/15/1995

Research committees

Head and Neck Cancer

Publication Information Expand/Collapse

1996

Evaluation of topotecan in recurrent or metastatic head and neck cancer. SWOG-9305.

RE Smith;D Lew;GI Rodriguez;SA Taylor;D Schuller American Society of Clinical Oncology 15:310(#868)

Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck, a phase II Southwest Oncology Group study.

RE Smith;D Lew;GI Rodriguez;SA Taylor;JF Ensley Investigational New Drugs 14:403-407